Theratechnologies Inc. (THTX)

NASDAQ: THTX · IEX Real-Time Price · USD
1.660
+0.180 (12.16%)
At close: Mar 28, 2024, 3:59 PM
1.680
+0.020 (1.20%)
After-hours: Mar 28, 2024, 7:59 PM EDT

Company Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe.

The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.

Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.

The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Theratechnologies Inc.
Theratechnologies logo
Country Canada
Founded 1993
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 103
CEO Paul Lévesque

Contact Details

Address:
2015 Peel Street, 5th Floor
Montreal, A8 H3A 1T8
Quebec, Canada
Phone 514-336-7800
Website theratech.com

Stock Details

Ticker Symbol THTX
Exchange NASDAQ
Fiscal Year December - November
Reporting Currency USD
CIK Code 0001512717
CUSIP Number 88338H100
ISIN Number CA88338H7040
SIC Code 2834

Key Executives

Name Position
Paul Lévesque President, Chief Executive Officer and Director
Philippe Dubuc M.B.A., MBA Senior Vice President and Chief Financial Officer
Jocelyn Lafond L.L.M., LL.B. General Counsel and Corporate Secretary
Dr. Christian Marsolais Ph.D. Senior Vice President and Chief Medical Officer
John Leasure Global Commercial Officer
Hon. Andre Dupras M.Sc. Vice President of Human Resources

Latest SEC Filings

Date Type Title
Mar 22, 2024 6-K Report of foreign issuer
Mar 22, 2024 6-K Report of foreign issuer
Mar 21, 2024 6-K Report of foreign issuer
Feb 29, 2024 6-K Report of foreign issuer
Feb 27, 2024 6-K Report of foreign issuer
Feb 21, 2024 20-F Annual and transition report of foreign private issuers
Feb 21, 2024 6-K Report of foreign issuer
Feb 15, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals